• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novartis Ag ADR (NY: NVS )

    107.08 +0.27 (+0.25%)
    Official Closing Price Updated: 7:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Novartis Ag ADR

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years
    Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous Kesimpta treatment led to better outcomes compared to those who switched from... 
    Via Benzinga
    Time To Invest And Or Trade In Bio-Tech Stocks?
    Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
    Via Talk Markets
    Topics ETFs
    Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
    Why NOVARTIS AG-SPONSORED ADR (NYSE:NVS) provides a good dividend, while having solid fundamentals. 
    Via Chartmill
    This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
    Via Benzinga
    Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    NYSE:NVS: good value for what you're paying.
    Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents. 
    Via Chartmill
    Uncovering Dividend Opportunities with NYSE:NVS.
    Balancing Dividends and Fundamentals: The Case of NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
    Via Chartmill
    Good technical signals and a possible breakout for NOVARTIS AG-SPONSORED ADR.
    The question on everyone's mind: Will NOVARTIS AG-SPONSORED ADR breakout? 
    Via Chartmill
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
    Via Benzinga
    Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
    Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential. 
    Via Benzinga
    S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
    Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Why NYSE:NVS is a Top Pick for Dividend Investors.
    Why the dividend investor may take a look at NOVARTIS AG-SPONSORED ADR (NYSE:NVS). 
    Via Chartmill
    Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage Study
    Novartis announced positive Phase 3 V-MONO study results for Leqvio, showing significant LDL-C reduction in low and moderate ASCVD risk patients, as the company continues to explore its potential in... 
    Via Benzinga
    Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
    From Lindy Biosciences
    Via Business Wire
    Galapagos Surges On An FDA Win For Its Rival To Gilead, Novartis; But There Are Some Caveats
    The company is gearing up to rival giants Gilead and Novartis with a potentially decentralized CAR-T process. 
    Via Investor's Business Daily
    Exposures Product Safety
    Siemens Healthineers To Buy Novartis Diagnostics To Bolster Cancer Scan Business In $220M Deal
    Siemens Healthineers to acquire Novartis' diagnostics division for over €200M, securing a vital supply of radioactive chemicals used in PET scans to enhance its European presence and cancer imaging... 
    Via Benzinga
    2 Unstoppable Healthcare Stocks to Buy Right Now With Less Than $200
    These companies' growth paths should only be briefly interrupted by headwinds. 
    Via The Motley Fool
    Judge Rules Against Novartis' Effort To Halt Generic Launch Of Its Top-Selling Heart Disease Drug
    Novartis faces a legal setback as a federal court allows MSN Pharmaceuticals to launch a generic version of Entresto, its top-selling heart-failure drug. The decision pressures Novartis to explore... 
    Via Benzinga
    The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
    Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 12, 2024) - Investorideas.com, a go-to investing platform covering biotech and... 
    Via Newsfile
    Exposures Product Safety
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
    Via Investor Brand Network
    FDA Approves Expanded Use Of Novartis' Rare Disease Drug Fabhalta For Kidney Disease
    Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.... 
    Via Benzinga
    Exposures Product Safety
    Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
    Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells. 
    Via Benzinga
    Topics Lawsuit
    Exposures Financial Legal
    Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
    EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
    From FN Media Group LLC
    Via GlobeNewswire
    Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
    From Arvinas Inc.
    Via GlobeNewswire
    AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
    The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market. 
    Via Benzinga
    Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
    The Nasdaq tumbled amid chip woes. 
    Via Investor's Business Daily
    Pharma Leader Beats on Earnings, But Shares Fall
    Novartis released its Q2 financial results. It beat expectations on EPS and revenue. However, shares fell, possibly due to bad news on one upcoming drug. 
    Via MarketBeat
    Topics Intellectual Property
    Exposures Intellectual Property
    Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
    NVS earnings call for the period ending June 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    42 43 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.